Literature DB >> 33328613

VDAC1 in the diseased myocardium and the effect of VDAC1-interacting compound on atrial fibrosis induced by hyperaldosteronism.

Hadar Klapper-Goldstein1,2, Ankit Verma3,4, Sigal Elyagon1,2, Roni Gillis1,2, Michael Murninkas1,2, Srinivas Pittala3,4, Avijit Paul3,4,5, Varda Shoshan-Barmatz3,6, Yoram Etzion7,8.   

Abstract

The voltage-dependent anion channel 1 (VDAC1) is a key player in mitochondrial function. VDAC1 serves as a gatekeeper mediating the fluxes of ions, nucleotides, and other metabolites across the outer mitochondrial membrane, as well as the release of apoptogenic proteins initiating apoptotic cell death. VBIT-4, a VDAC1 oligomerization inhibitor, was recently shown to prevent mitochondrial dysfunction and apoptosis, as validated in mouse models of lupus and type-2 diabetes. In the present study, we explored the expression of VDAC1 in the diseased myocardium of humans and rats. In addition, we evaluated the effect of VBIT-4 treatment on the atrial structural and electrical remodeling of rats exposed to excessive aldosterone levels. Immunohistochemical analysis of commercially available human cardiac tissues revealed marked overexpression of VDAC1 in post-myocardial infarction patients, as well as in patients with chronic ventricular dilatation\dysfunction. In agreement, rats exposed to myocardial infarction or to excessive aldosterone had a marked increase of VDAC1 in both ventricular and atrial tissues. Immunofluorescence staining indicated a punctuated appearance typical for mitochondrial-localized VDAC1. Finally, VBIT-4 treatment attenuated the atrial fibrotic load of rats exposed to excessive aldosterone without a notable effect on the susceptibility to atrial fibrillation episodes induced by burst pacing. Our results indicate that VDAC1 overexpression is associated with myocardial abnormalities in common pathological settings. Our data also indicate that inhibition of the VDAC1 can reduce excessive fibrosis in the atrial myocardium, a finding which may have important therapeutic implications. The exact mechanism\s of this beneficial effect need further studies.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33328613      PMCID: PMC7744539          DOI: 10.1038/s41598-020-79056-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  59 in total

1.  Aldosterone pathway in atrial fibrillation.

Authors:  Adam S Budzikowski
Journal:  Cardiology       Date:  2011-07-05       Impact factor: 1.869

2.  An implantable system for long-term assessment of atrial fibrillation substrate in unanesthetized rats exposed to underlying pathological conditions.

Authors:  Hadar Klapper-Goldstein; Michael Murninkas; Roni Gillis; Wesam Mulla; Eran Levanon; Sigal Elyagon; Ronen Schuster; Dor Danan; Hagit Cohen; Yoram Etzion
Journal:  Sci Rep       Date:  2020-01-17       Impact factor: 4.379

Review 3.  Latest aspects of aldosterone actions on the heart muscle.

Authors:  A A Kritis; C P Gouta; E I Liaretidou; K I Kallaras
Journal:  J Physiol Pharmacol       Date:  2016-02       Impact factor: 3.011

Review 4.  Role of apoptosis in remodeling after myocardial infarction.

Authors:  Genzou Takemura; Hisayoshi Fujiwara
Journal:  Pharmacol Ther       Date:  2004-10       Impact factor: 12.310

5.  Oligomerization of the mitochondrial protein voltage-dependent anion channel is coupled to the induction of apoptosis.

Authors:  Nurit Keinan; Dalia Tyomkin; Varda Shoshan-Barmatz
Journal:  Mol Cell Biol       Date:  2010-10-11       Impact factor: 4.272

6.  VDAC/porin is present in sarcoplasmic reticulum from skeletal muscle.

Authors:  V Shoshan-Barmatz; N Hadad; W Feng; I Shafir; I Orr; M Varsanyi; L M Heilmeyer
Journal:  FEBS Lett       Date:  1996-05-20       Impact factor: 4.124

7.  Resveratrol protects cardiomyocytes against anoxia/reoxygenation via dephosphorylation of VDAC1 by Akt-GSK3 β pathway.

Authors:  Mengyuan Tian; Yongyan Xie; Yan Meng; Wen Ma; Zhihong Tong; Xiaomei Yang; Songqing Lai; Yue Zhou; Ming He; Zhangping Liao
Journal:  Eur J Pharmacol       Date:  2018-11-14       Impact factor: 4.432

Review 8.  Apoptosis and angiogenesis: an evolving mechanism for fibrosis.

Authors:  Ariel Johnson; Luisa Ann DiPietro
Journal:  FASEB J       Date:  2013-06-19       Impact factor: 5.191

9.  VDAC1 at the crossroads of cell metabolism, apoptosis and cell stress.

Authors:  Varda Shoshan-Barmatz; Eduardo N Maldonado; Yakov Krelin
Journal:  Cell Stress       Date:  2017-10-01
View more
  5 in total

Review 1.  Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease.

Authors:  Anqi Li; Meng Gao; Bilin Liu; Yuan Qin; Lei Chen; Hanyu Liu; Huayan Wu; Guohua Gong
Journal:  Cell Death Dis       Date:  2022-05-09       Impact factor: 9.685

2.  Targeting calcium-mediated inter-organellar crosstalk in cardiac diseases.

Authors:  Mohit M Hulsurkar; Satadru K Lahiri; Jason Karch; Meng C Wang; Xander H T Wehrens
Journal:  Expert Opin Ther Targets       Date:  2022-04-25       Impact factor: 6.797

Review 3.  Research Progress of Myocardial Fibrosis and Atrial Fibrillation.

Authors:  Guangling Li; Jing Yang; Demei Zhang; Xiaomei Wang; Jingjing Han; Xueya Guo
Journal:  Front Cardiovasc Med       Date:  2022-07-25

4.  Mitochondrial DNA in Uremia and New Targets to Treat Myocardial Hypertrophy in the Cardiorenal Syndrome.

Authors:  George Bayliss
Journal:  JACC Basic Transl Sci       Date:  2022-08-22

Review 5.  Mitochondrial VDAC1: A Potential Therapeutic Target of Inflammation-Related Diseases and Clinical Opportunities.

Authors:  Hang Hu; Linlin Guo; Jay Overholser; Xing Wang
Journal:  Cells       Date:  2022-10-10       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.